NCT02490930View on ClinicalTrials.gov

A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions
GlioblastomaAnaplastic Astrocytoma
Interventions
DRUG

Fingolimod

Oral fingolimod will be given 1 week prior to the initiation of concurrent radiation and temozolomide and will be discontinued immediately upon completion of the six weeks of therapy.

Trial Locations (1)

21287

The Johns Hopkins University, Baltimore

All Listed Sponsors
lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT02490930 - A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma | Biotech Hunter | Biotech Hunter